Popular GLP-1 receptor agonist medications—widely prescribed for weight management and type 2 diabetes under brand names such as Ozempic, Wegovy, Mounjaro, Zepbound, Victoza, and Trulicity—have been linked to an unexpected set of dermatological side effects involving fingernails, hair, and the scalp. A multinational study presented at the European Academy of Dermatology and Venereology (EADV) Congress 2026 has revealed that individuals taking these blockbuster therapies report significantly higher rates of nail detachment, discoloration, and various hair and scalp complications compared to control groups.
The investigation marks the first controlled study to systematically examine the relationship between GLP-1 medications and nail health. While prior accounts of adverse nail reactions during treatment were largely anecdotal, the new research provides a structured comparison that highlights broad patterns in physical symptoms among patients managing obesity and diabetes.
Researchers found that 39% of GLP-1 users experienced nail detachment—a clinical condition known as onycholysis, in which the nail separates from the underlying nail bed—compared with just 9% of individuals in a control group who had never taken the medications. Furthermore, nail discoloration proved to be considerably more common among those on the therapy, with two-thirds of users overall reporting at least one distinct nail disorder.
Unexpected Nail Problems Among GLP-1 Users
In recent years, GLP-1 receptor agonists have transformed the medical landscape for obesity and type 2 diabetes. By acting on intricate hormone signaling systems that regulate blood sugar levels and suppress appetite, these drugs have proven extraordinarily effective as tools for improving metabolic health and supporting sustained weight loss.
However, as millions of patients worldwide begin utilizing these therapies, medical researchers continue to investigate their systemic effects across various organs and tissues of the body. Until recently, clinical literature regarding nail changes during GLP-1 treatment consisted primarily of isolated patient reports rather than rigorous, controlled comparisons.
To bridge this data gap, researchers designed a multinational study examining 575 individuals using GLP-1 medications and compared them against a control group of 1,329 individuals diagnosed with type 2 diabetes and/or obesity who had never used the drugs. Study participants were recruited from diverse clinical populations across France, the United States, Brazil, and Mexico.
The compiled results revealed a consistent pattern across multiple health indicators. Overall, 66% of GLP-1 users reported experiencing at least one type of nail disorder, compared with 53% of individuals in the control group. Nail discoloration showed an especially pronounced difference, affecting 46% of medication users versus 17% of nonusers.
Most strikingly, nail detachment was more than four times as common among those currently taking GLP-1 medications, pointing to an area of patient care that clinicians may need to monitor more closely as prescriptions continue to rise globally.
Weight Loss Alone May Not Explain the Nail Changes
A central question facing the research team was whether these reported nail problems might simply be secondary effects of rapid weight loss, rather than a direct physiological consequence of the medications themselves. Significant fluctuations in body weight and accompanying dietary changes can influence nutritional status and other physiological processes, which are known to impact the health of both hair and nails.
To test this hypothesis, the researchers analyzed whether weight loss alone could account for the statistical differences observed. Interestingly, they discovered that weight loss did not fully explain the variations. Even when the analytical models were restricted exclusively to participants who had successfully lost weight, GLP-1 users continued to report significantly higher rates of nail complications than control participants who had not used the drugs.
"Until now, nail changes associated with GLP-1 therapies had essentially been anecdotal," said study author Dr. Charles Taïeb. "Our findings show a clear association, but they also underline an important point: not everything that happens during GLP-1 treatment is necessarily caused by the treatment itself."
The researchers cautioned that their findings do not definitively prove that GLP-1 drugs directly cause nail disorders. Notably, approximately half of the medication users surveyed stated that they had noticed nail problems even before beginning their pharmaceutical treatment.
When the research team adjusted their statistical models to account for pre-existing skin conditions and underlying nutritional deficiencies, some of the performance gaps between the groups narrowed. Nevertheless, nail detachment and discoloration remained approximately two to three times more common among GLP-1 users even after these confounding factors were factored into the analysis.
Scientists Also Find Higher Rates of Hair Loss and Scalp Problems
The unexpected dermatological findings extended well beyond fingernails. A companion study evaluating the exact same cohort of participants identified substantial differences in hair and scalp health among individuals utilizing GLP-1 medications.
Half of all GLP-1 users reported unusual hair loss, compared with 34% of nonusers in the control group. Reduced hair volume or lower overall hair density was also substantially more frequent, affecting 42% of users versus 19% of the control group.
When researchers isolated cases of hair loss that specifically began after treatment was initiated, the discrepancy widened further. Post-treatment hair shedding was reported by 26% of GLP-1 users compared with 12% of nonusers, making it more than twice as common in the medication group. Additionally, visible scalp redness occurred at approximately three times the frequency among those taking GLP-1 drugs.
A particularly noteworthy discovery was that hair loss rarely presented as an isolated symptom. The vast majority of users who reported hair shedding also experienced concurrent scalp symptoms, including persistent itching, redness, or flaking skin.
These accompanying clinical signs introduced the possibility that localized inflammation could be contributing to the observed changes, rather than the hair loss being driven exclusively by the physiological shock of rapid weight reduction.
"This suggests that what is happening on the scalp may go beyond the classical shedding seen after rapid weight loss and involve an inflammatory component," explained study author Dr. Bruno Halioua. "Scalp inflammation was the rule rather than the exception, which clinicians do not currently look for and which may be treatable. Taken together, our findings suggest that factors beyond weight loss alone may contribute to the hair, scalp and nail changes observed among GLP-1 users."
What the Findings Mean for People Taking GLP-1 Drugs
Despite the relatively high frequency of reported symptoms, the study’s authors emphasized that their discoveries should prompt clinical awareness and patient observation rather than panic or unnecessary discontinuation of beneficial therapies.
"These changes are frequent, usually benign, and are not a reason to stop an effective treatment on one’s own initiative," the researchers noted. They advised that anyone who notices unexpected hair shedding, an itchy or red scalp, or structural nail changes should discuss these symptoms with their primary healthcare provider rather than independently stopping their medication regimen.
The research team also pointed out important limitations inherent in the current data. Both investigations were structured as cross-sectional studies, meaning they captured patient-reported experiences at a single point in time without longitudinally tracking how symptoms evolved from initiation through long-term use. Additionally, the findings relied primarily on symptoms reported subjectively by participants rather than standardized clinical examinations conducted by dermatologists.
Consequently, while the studies successfully reveal consistent clinical patterns and associations, they cannot definitively establish whether GLP-1 medications directly caused the reported nail, hair, or scalp issues.
To explore these questions with greater precision, the research team is preparing prospective studies designed to follow patients from the very beginning of their treatment journeys. These upcoming investigations will incorporate standardized skin, hair, and nail evaluations alongside biological monitoring to determine the exact timeline of when these changes first appear, uncover the underlying biological mechanisms, and track whether the conditions resolve over time.
The research received institutional support from DUCRAY Laboratories, a division of the Pierre Fabre Group specializing in dermatological and hair care products aimed at managing skin and scalp conditions and supporting overall patient quality of life.